SBK2-Driven NDUFV1 Phosphorylation and Translocation Limits Cardiac Hypertrophy

Yazhou Sun1,2, Qinghua Wu1,2, Fang Lei3

  • 1Department of Cardiology, Renmin Hospital of Wuhan University, China (Y.S., Q. Wu, L.L., L.Z., L.W., Z.Y., X.-J.Z., H.L., Z.-G.S.).

Insights

Src homology 3 domain-binding kinase 2 (SBK2) restrains cardiac hypertrophy by enhancing mitochondrial complex I function through NDUFV1 phosphorylation. This discovery reveals a new signaling pathway for heart failure and potential therapeutic targets.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Medicine
  • Molecular Cardiology

Background:

  • Heart failure is a major health burden, often driven by pathological cardiac hypertrophy.
  • Mitochondrial dysfunction, specifically impaired mitochondrial complex I activity, is critical in disease progression.
  • Regulatory mechanisms of mitochondrial dysfunction in heart failure are not well understood.

Purpose of the Study:

  • To investigate the role of Src homology 3 domain-binding kinase 2 (SBK2) in cardiac hypertrophy.
  • To determine if SBK2 modulates mitochondrial complex I function in the context of heart failure.
  • To elucidate the molecular mechanisms by which SBK2 influences cardiac function.

Main Methods:

  • Cross-species transcriptomic screening and UK Biobank analyses identified SBK2 as a potential risk factor.
  • Loss- and gain-of-function studies in cardiomyocytes and mice were performed.
  • Proteomic, interactome, and biochemical analyses identified SBK2 substrates and downstream effects on mitochondrial function.

Main Results:

  • SBK2 expression was reduced in hypertrophic hearts; SBK2 overexpression attenuated hypertrophy and fibrosis.
  • SBK2 directly phosphorylates NDUFV1 (NADH: ubiquinone oxidoreductase core subunit V1) at serine 251, enhancing its mitochondrial import.
  • This phosphorylation promotes mitochondrial complex I activity, respiratory supercomplex assembly, and overall mitochondrial health, protecting against hypertrophy.

Conclusions:

  • SBK2 acts as an upstream kinase, linking cytosolic signaling to mitochondrial protein import and function.
  • The SBK2-NDUFV1 axis sustains complex I integrity and mitochondrial function, restraining pathological cardiac hypertrophy.
  • This pathway represents a novel therapeutic target for heart failure and related conditions.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...